Valuation: China Biotech Services Holdings Limited

Market Cap 48Cr 6.16Cr 5.5Cr 5.08Cr 4.6Cr 8.61Cr 584.65Cr 8.76Cr 61Cr 24Cr 306.32Cr 23Cr 23Cr 965.74Cr P/E 2024
-2.49x
P/E 2025 -11.2x
Enterprise Value 87Cr 11Cr 9.86Cr 9.11Cr 8.25Cr 15Cr 1.05TCr 16Cr 109.6Cr 43Cr 549.11Cr 41Cr 41Cr 1.73TCr EV / Sales 2024
9.45x
EV / Sales 2025 15.7x
Free-Float
35.46%
Yield 2024 *
-
Yield 2025 -
28/08 China Biotech Services Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2026 CI
12/08 China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2026 CI
12/08 China Biotech Services Holdings Limited and Stella Pharma Corporation Enter Master Collaboration Agreement for Commercialisation of BNCT Drug CI
03/08 China Biotech Services Holdings Limited's Japan, Pengbo Medical Technology Co., Ltd. Present of Initial Follow-Up Findings of Boron Neutron Capture Therapy At the 22Nd Congress on Neutron Capture Therapy CI
18/05 China Biotech Services' unit disposes entire stake in PHC Medical Diagnostic Centre, others RE
30/04 China Biotech Services says He Xun resigns as executive director RE
30/04 China Biotech Services Holdings Limited Announces Resignation He Xun as Executive Director, Effective May 1, 2026 CI
29/04 China Biotech Services Holdings Limited Auditor Raises 'Going Concern' Doubt CI
27/03 China Biotech Services Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2025 CI
06/03 China Biotech Services expects FY net loss of not more than HK$100 million RE
06/03 China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2025 CI
20/02 China Biotech Services Holdings Limited announced that it has received HKD 272.3 million in funding from Wealth Strategy Holding Ltd CI
30/12 China Biotech Services to issue convertible bonds RE
1 day-1.00%
1 week-2.94%
Current month-18.85%
1 month-7.48%
3 months-22.66%
6 months-26.12%
Current year-37.34%
1 week 0.48
Extreme 0.48
0.54
1 month 0.48
Extreme 0.48
0.62
Current year 0.3
Extreme 0.3
0.92
1 year 0.3
Extreme 0.3
1.04
3 years 0.25
Extreme 0.25
1.33
5 years 0.25
Extreme 0.25
2.64
10 years 0.23
Extreme 0.23
2.64
Manager TitleAgeSince
Director of Finance/CFO - -
Compliance Officer 55 26/05/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 60 07/08/2017
Director/Board Member 44 15/09/2017
Chairman 55 28/08/2017
Date Insider Type Main position Quantity % Market Cap. Importance
30/03/26 Other

Chairman

36,00,000 0.3690%
02/09/24 Other

Director

32,20,000 0.3300%
13/06/24 Other

Director

50,00,000 0.5191%
Change 5-day change 1-year change 3-year change Capi.($)
-1.00%-2.94%-44.38%-28.26% 6.16Cr
-1.07%+1.20%+14.09%+35.52% 12TCr
+0.37%+2.22%+4.92%+103.82% 10TCr
+0.64%+2.67%+109.83%+890.32% 5.82TCr
+1.75%+2.27%-5.92%+83.08% 2.91TCr
-0.57%+2.93%+32.78%+95.74% 2.67TCr
-0.30%+3.46%+17.70%+65.59% 2.67TCr
-0.81%+0.45%+27.60%+378.95% 2.16TCr
-2.46%-5.71%-23.17%-7.12% 1.96TCr
-0.68%+2.72%+4.02%+82.89% 1.89TCr
Average -0.41%+0.53%+13.75%+170.05% 4.22TCr
Weighted average by Cap. -0.25%+1.64%+23.63%+196.63%

Financials

2024 2025
Net sales 7.05Cr 89.91L 80.29L 74.17L 67.22L 1.26Cr 85Cr 1.28Cr 8.93Cr 3.53Cr 45Cr 3.37Cr 3.3Cr 140.98Cr 7.35Cr 93.73L 83.7L 77.32L 70.07L 1.31Cr 89Cr 1.33Cr 9.3Cr 3.68Cr 47Cr 3.52Cr 3.44Cr 146.97Cr
Net income -20Cr -2.53Cr -2.26Cr -2.08Cr -1.89Cr -3.53Cr -239.85Cr -3.59Cr -25Cr -9.93Cr -125.67Cr -9.48Cr -9.28Cr -396.2Cr -6.88Cr -87.7L -78.32L -72.35L -65.57L -1.23Cr -83Cr -1.25Cr -8.71Cr -3.45Cr -44Cr -3.29Cr -3.22Cr -137.52Cr
Net Debt 17Cr 2.15Cr 1.92Cr 1.78Cr 1.61Cr 3.01Cr 204.47Cr 3.06Cr 21Cr 8.47Cr 107.13Cr 8.08Cr 7.91Cr 337.76Cr 38Cr 4.88Cr 4.36Cr 4.03Cr 3.65Cr 6.83Cr 463.4Cr 6.94Cr 48Cr 19Cr 242.79Cr 18Cr 18Cr 765.45Cr
Projected Income Statement - Annual - China Biotech Services Holdings Limited
Logo China Biotech Services Holdings Limited
China Biotech Services Holdings Ltd, formerly Rui Kang Pharmaceutical Group Investments Ltd, is an investment holding company principally engaged in the provision of medical health check services. The Company operates its business through six segments. The Medical and Health Related Services segment provides medical laboratory testing services and health check services. The Insurance Brokerage segment is engaged in the provision of brokerage services. The Immunotherapy segment provides tumor immune call therapy, immune cell storage and health management services. The Pharmaceutical Products segment is engaged in the manufacture, research and development, sale and distribution of health related and pharmaceutical products. The Securities segment is engaged in the trading of securities. The Others segment is engaged in the money lending business and provision of logistic services.
Employees
166
Date Price Change Volume
23/26/23 HK$0.4950 -1.00% 2,50,000
22/26/22 HK$0.5000 -1.96% 2,75,000
21/26/21 HK$0.5100 -5.56% 90,000
20/26/20 HK$0.5400 +5.88% 2,20,000
16/26/16 HK$0.5100 -1.92% 10,000
  1. Stock Market
  2. Stocks
  3. 8037 Stock